These agents, known for their dual impact on both immune modulation and metabolic improvement, offer a unique therapeutic potential in managing immune-mediated inflammatory diseases ( 3.2 GLP-1RAs in psoriatic arthritis The therapeutic landscape of PsA is currently dominated by targeted agents that inhibit key inflammatory pathways, including TNF inhibitors (e.g., adalimumab, etanercept), IL17 inhibitors (e.g., secukinumab, ixekizumab), IL-23 inhibitors (e.g., guselkumab, risankizumab), and Janus kinase (JAK) inhibitors such as upadacitinib and tofacitinib ( Several studies have reported an inverse relationship between BMI and therapeutic efficacy, indicating that obesity may attenuate clinical responses to biologic disease modifying anti-rheumatic drugs (bDMARDs)
For more information on fatty liver diseases, see the section on Disease Prevention
L'ANSM qualifie explicitement ces produits de mdicaments au sens du Code de la sant publique, ce qui rend leur vente et leur administration illgales en France en dehors d'une indication thrapeutique autorise
Sterne JAC, Savovi J, Page MJ, et al
Plumb